SlideShare a Scribd company logo
Phase transition Early-Invasive Lung Cancer and Blood Cell Circuit
No disclosures
OBJECTIVE: The effect of blood cell circuit on the phase transition (PT) early-invasive lung cancer (LC) was
investigated.
METHODS: We analyzed data of 770 consecutive non-small cell LC patients (LCP) (age=57.6±8.3 years; tumor
size=4.1±2.4 cm) radically operated (R0) and monitored in 1985-2021 (m=661, f=109; upper lobectomies=278, lower
lobectomies=177, middle lobectomies=18, bilobectomies=42, pneumonectomies=255, mediastinal lymph node
dissection=770; combined procedures with resection of trachea, carina, atrium, aorta, VCS, vena azygos, pericardium,
liver, diaphragm, ribs, esophagus=194; T1=321, T2=255, T3=133, T4=61; N0=517, N1=131, N2=122, M0=770; G1=194,
G2=243, G3=333; squamous=417, adenocarcinoma=303, large cell=50; early LCP=215; invasive LCP=555; central LC=291;
periferical LC=479. Variables selected for study were input levels of blood cell circuit, sex, age, TNMG. Differences
between groups were evaluated using discriminant analysis, clustering, nonlinear estimation, structural equation
modeling, Monte Carlo, bootstrap simulation and neural networks computing.
RESULTS: It was revealed that separation of LCP with early LC (n=215) from invasive LCP (n=555) significantly
depended on: Hb, leucocytes (abs, total), thrombocytes (abs, tot), erythrocytes (abs, tot), segmented neutrophils (%, abs,
total), stick neutrophils (%, abs, total), lymphocytes (%), monocytes (abs, tot), ESS, coagulation time, fibrinogen, cell ratio
factors (CRF) (ratio between cancer cells- CC and blood cells subpopulations), tumor size, age, tumor growth, T1-4, G1-3,
PT N0---N12 (P=0.046-0.000). Neural networks computing, genetic algorithm selection and bootstrap simulation revealed
relationships of PT early—invasive cancer and CRF: healthy cells/CC (rank=1), erythrocytes/CC (2), stick neutrophils/CC
(3), thrombocytes/CC (4), eosinophils/CC (5), segmented neutrophils/CC (6), lymphocytes/CC (7), monocytes/CC (8),
leucocytes/CC (9). Correct classification PT early—invasive cancer was 100% by neural networks computing (area under
ROC curve=1.0; error=0.0).
CONCLUSION: Blood cell circuit significantly influenced the phase transition early—invasive lung cancer.
Oleg Kshivets, MD, PhD e-mail: okshivets@yahoo.com
Surgery Department, Roshal Hospital, Moscow, Russia a
Effect
GLZ results Distribution :
NORMAL Link function: LOG
Degr. of
Freedom
Wald
Stat.
p
Intercept 1 7.0733 0.007824
Tumor Size 1 17.0855 0.000036
Erythrocytes 1 26.7452 0.000000
Eosinophils 1 10.1318 0.001457
Stick Neutrophils 1 5.3924 0.020225
Segmented Neutrophils 1 7.1446 0.007519
Lymphocytes 1 6.7744 0.009248
Monocytes 1 6.6979 0.009653
Monocytes (abs) 1 6.4758 0.010935
Leucocytes/Cancer Cells 1 12.4650 0.000415
Eosinophils/Cancer Cells 1 5.5420 0.018566
Segmented Neutrophils/Cancer Cells 1 9.1786 0.002449
Lymphocytes/Cancer Cells 1 7.9876 0.004710
Healthy Cells/Cancer Cells 1 54.3179 0.000000
Erythrocytes (tot) 1 25.8367 0.000000
Leucocytes (tot) 1 12.3061 0.000451
Eosinophils (tot) 1 16.5695 0.000047
Stick Neutrophils (tot) 1 9.7226 0.001820
Stick Neutrophils (tot) 1 12.3151 0.000449
Lymphocytes (tot) 1 11.6562 0.000640
Monocytes (tot) 1 5.3094 0.021211
Tumor Growth 1 10.0305 0.001540
G1-3 2 14.4966 0.000711
T1-4 3 145.8011 0.000000
Phase Transition N0----N12 1 61.7560 0.000000
Neural Networks: n=770;
Baseline Error=0.000;
Area under ROC Curve=1.000;
Correct Classification Rate=100%
Rank Sensitivity
Healthy Cells/Cancer Cells 1 2639
Erythrocytes/Cancer Cells 2 900
Stick Neutrophils/Cancer Cells 3 821
Thrombocytes/Cancer Cells 4 709
Eosinophils/Cancer Cells 5 606
Segmented Neutrophils/Cancer Cells 6 485
Lymphocytes/Cancer Cells 7 372
Monocytes/Cancer Cells 8 342
Leucocytes/Cancer Cells Stick 9 216
Bootstrap Simulation n=770
Significant Factors
(Number of Samples=3333)
Rank Kendal Tau-A P<
Healthy Cells/Cancer Cells 1 0.607 0.000
Erythrocytes/Cancer Cells 2 0.596 0.000
Thrombocytes/Cancer Cells 3 0.561 0.000
Leucocytes/Cancer Cells 4 0.498 0.000
Segmented Neutrophils/Cancer Cells 5 0.472 0.000
Lymphocytes/Cancer Cells 6 0.450 0.000
Tumor Size 7 -0.399 0.000
T1-4 8 -0.317 0.000
Monocytes/Cancer Cells 9 0.263 0.000
Eosinophils/Cancer Cells 10 0.233 0.000
Phase Transition N0---N12 11 -0.183 0.000
Surgery along 12 0.151 0.000
Pneumonectomies/Lobectomies 13 -0.149 0.000
ESS 14 -0.149 0.000
Procedure Type 15 0.148 0.000
Segmented Neutrophils (abs) 16 -0.125 0.000
Coagulation Time 17 -0.109 0.000
G1-3 18 -0.091 0.001
Adjuvant Treatment 19 -0.089 0.001
Tumor Growth 20 0.079 0.05
Stick Neutrophils (abs) 21 -0.076 0.05
Stick Neutrophils (%) 22 -0.074 0.05
Histology 23 0.073 0.05
#358

More Related Content

What's hot

Kshivets O. Esophageal and Cardioesophageal Cancer Surgery
Kshivets O. Esophageal and Cardioesophageal Cancer SurgeryKshivets O. Esophageal and Cardioesophageal Cancer Surgery
Kshivets O. Esophageal and Cardioesophageal Cancer Surgery
Oleg Kshivets
 
Kshivets O. Esophageal Cancer Surgery
Kshivets O. Esophageal Cancer SurgeryKshivets O. Esophageal Cancer Surgery
Kshivets O. Esophageal Cancer Surgery
Oleg Kshivets
 
Kshivets yokohama iaslc2017
Kshivets yokohama iaslc2017Kshivets yokohama iaslc2017
Kshivets yokohama iaslc2017
Oleg Kshivets
 
Kshivets O. Cancer, Computer Sciences and Alive Supersystems
Kshivets O. Cancer, Computer Sciences and Alive SupersystemsKshivets O. Cancer, Computer Sciences and Alive Supersystems
Kshivets O. Cancer, Computer Sciences and Alive Supersystems
Oleg Kshivets
 
Kshivets O. Lung Cancer Surgery: Synergetics and Prediction
Kshivets O. Lung Cancer Surgery: Synergetics and PredictionKshivets O. Lung Cancer Surgery: Synergetics and Prediction
Kshivets O. Lung Cancer Surgery: Synergetics and Prediction
Oleg Kshivets
 
Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...
Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...
Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...
Oleg Kshivets
 
Kshivets Oleg Local Advanced Gastric Cancer: Optimization of Management
Kshivets Oleg Local Advanced Gastric Cancer: Optimization of ManagementKshivets Oleg Local Advanced Gastric Cancer: Optimization of Management
Kshivets Oleg Local Advanced Gastric Cancer: Optimization of Management
Oleg Kshivets
 
Kshivets iaslc denver2021
Kshivets iaslc denver2021Kshivets iaslc denver2021
Kshivets iaslc denver2021
Oleg Kshivets
 
Kshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer Surgery
Oleg Kshivets
 
2021 esmo world_gi_poster_kshivets
2021 esmo world_gi_poster_kshivets2021 esmo world_gi_poster_kshivets
2021 esmo world_gi_poster_kshivets
Oleg Kshivets
 
Kshivets O. Lung Cancer: Optimal Treatment Strategies
Kshivets O.  Lung Cancer: Optimal Treatment StrategiesKshivets O.  Lung Cancer: Optimal Treatment Strategies
Kshivets O. Lung Cancer: Optimal Treatment Strategies
Oleg Kshivets
 
Kshivets O. Synergetics and Survival of Lung Cancer Patients
Kshivets O. Synergetics and Survival of Lung Cancer PatientsKshivets O. Synergetics and Survival of Lung Cancer Patients
Kshivets O. Synergetics and Survival of Lung Cancer Patients
Oleg Kshivets
 
Kshivets ASCO Chicago2020
Kshivets ASCO Chicago2020Kshivets ASCO Chicago2020
Kshivets ASCO Chicago2020
Oleg Kshivets
 
Kshivets chicago2016
Kshivets chicago2016Kshivets chicago2016
Kshivets chicago2016
Oleg Kshivets
 
Kshivets O. Esophageal Cancer Surgery
Kshivets O.  Esophageal Cancer SurgeryKshivets O.  Esophageal Cancer Surgery
Kshivets O. Esophageal Cancer Surgery
Oleg Kshivets
 
Kshivets O. Lung Cancer Stage III Surgery
Kshivets O. Lung Cancer Stage III Surgery Kshivets O. Lung Cancer Stage III Surgery
Kshivets O. Lung Cancer Stage III Surgery
Oleg Kshivets
 
Kshivets O. Lung Cancer Surgery: Prognosis
Kshivets O. Lung Cancer Surgery: PrognosisKshivets O. Lung Cancer Surgery: Prognosis
Kshivets O. Lung Cancer Surgery: Prognosis
Oleg Kshivets
 
Kshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer Surgery
Oleg Kshivets
 
Kshivets esophageal cancer_management
Kshivets esophageal cancer_managementKshivets esophageal cancer_management
Kshivets esophageal cancer_management
Oleg Kshivets
 
Kshivets O. Cancer, Synergetics, Computer Sciences and Alive Supersystems
Kshivets O. Cancer, Synergetics, Computer Sciences and Alive SupersystemsKshivets O. Cancer, Synergetics, Computer Sciences and Alive Supersystems
Kshivets O. Cancer, Synergetics, Computer Sciences and Alive Supersystems
Oleg Kshivets
 

What's hot (20)

Kshivets O. Esophageal and Cardioesophageal Cancer Surgery
Kshivets O. Esophageal and Cardioesophageal Cancer SurgeryKshivets O. Esophageal and Cardioesophageal Cancer Surgery
Kshivets O. Esophageal and Cardioesophageal Cancer Surgery
 
Kshivets O. Esophageal Cancer Surgery
Kshivets O. Esophageal Cancer SurgeryKshivets O. Esophageal Cancer Surgery
Kshivets O. Esophageal Cancer Surgery
 
Kshivets yokohama iaslc2017
Kshivets yokohama iaslc2017Kshivets yokohama iaslc2017
Kshivets yokohama iaslc2017
 
Kshivets O. Cancer, Computer Sciences and Alive Supersystems
Kshivets O. Cancer, Computer Sciences and Alive SupersystemsKshivets O. Cancer, Computer Sciences and Alive Supersystems
Kshivets O. Cancer, Computer Sciences and Alive Supersystems
 
Kshivets O. Lung Cancer Surgery: Synergetics and Prediction
Kshivets O. Lung Cancer Surgery: Synergetics and PredictionKshivets O. Lung Cancer Surgery: Synergetics and Prediction
Kshivets O. Lung Cancer Surgery: Synergetics and Prediction
 
Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...
Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...
Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...
 
Kshivets Oleg Local Advanced Gastric Cancer: Optimization of Management
Kshivets Oleg Local Advanced Gastric Cancer: Optimization of ManagementKshivets Oleg Local Advanced Gastric Cancer: Optimization of Management
Kshivets Oleg Local Advanced Gastric Cancer: Optimization of Management
 
Kshivets iaslc denver2021
Kshivets iaslc denver2021Kshivets iaslc denver2021
Kshivets iaslc denver2021
 
Kshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer Surgery
 
2021 esmo world_gi_poster_kshivets
2021 esmo world_gi_poster_kshivets2021 esmo world_gi_poster_kshivets
2021 esmo world_gi_poster_kshivets
 
Kshivets O. Lung Cancer: Optimal Treatment Strategies
Kshivets O.  Lung Cancer: Optimal Treatment StrategiesKshivets O.  Lung Cancer: Optimal Treatment Strategies
Kshivets O. Lung Cancer: Optimal Treatment Strategies
 
Kshivets O. Synergetics and Survival of Lung Cancer Patients
Kshivets O. Synergetics and Survival of Lung Cancer PatientsKshivets O. Synergetics and Survival of Lung Cancer Patients
Kshivets O. Synergetics and Survival of Lung Cancer Patients
 
Kshivets ASCO Chicago2020
Kshivets ASCO Chicago2020Kshivets ASCO Chicago2020
Kshivets ASCO Chicago2020
 
Kshivets chicago2016
Kshivets chicago2016Kshivets chicago2016
Kshivets chicago2016
 
Kshivets O. Esophageal Cancer Surgery
Kshivets O.  Esophageal Cancer SurgeryKshivets O.  Esophageal Cancer Surgery
Kshivets O. Esophageal Cancer Surgery
 
Kshivets O. Lung Cancer Stage III Surgery
Kshivets O. Lung Cancer Stage III Surgery Kshivets O. Lung Cancer Stage III Surgery
Kshivets O. Lung Cancer Stage III Surgery
 
Kshivets O. Lung Cancer Surgery: Prognosis
Kshivets O. Lung Cancer Surgery: PrognosisKshivets O. Lung Cancer Surgery: Prognosis
Kshivets O. Lung Cancer Surgery: Prognosis
 
Kshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer Surgery
 
Kshivets esophageal cancer_management
Kshivets esophageal cancer_managementKshivets esophageal cancer_management
Kshivets esophageal cancer_management
 
Kshivets O. Cancer, Synergetics, Computer Sciences and Alive Supersystems
Kshivets O. Cancer, Synergetics, Computer Sciences and Alive SupersystemsKshivets O. Cancer, Synergetics, Computer Sciences and Alive Supersystems
Kshivets O. Cancer, Synergetics, Computer Sciences and Alive Supersystems
 

Similar to Kshivets elcc2022

Kshivets IASLC_Vienna2016
Kshivets IASLC_Vienna2016Kshivets IASLC_Vienna2016
Kshivets IASLC_Vienna2016
Oleg Kshivets
 
Lung Cancer: Precise Prediction
Lung Cancer: Precise PredictionLung Cancer: Precise Prediction
Lung Cancer: Precise Prediction
Oleg Kshivets
 
Kshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdfKshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdf
Oleg Kshivets
 
Kshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdfKshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdf
Oleg Kshivets
 
Kshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer Surgery
Oleg Kshivets
 
Kshivets iaslc singapore2020
Kshivets iaslc singapore2020Kshivets iaslc singapore2020
Kshivets iaslc singapore2020
Oleg Kshivets
 
Kshivets iaslc denver2015
Kshivets iaslc denver2015Kshivets iaslc denver2015
Kshivets iaslc denver2015
Oleg Kshivets
 
Kshivets_SPB_WSCTS2022Lung.pdf
Kshivets_SPB_WSCTS2022Lung.pdfKshivets_SPB_WSCTS2022Lung.pdf
Kshivets_SPB_WSCTS2022Lung.pdf
Oleg Kshivets
 
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Oleg Kshivets
 
Kshivets wscts2018 ljubljana
Kshivets wscts2018 ljubljanaKshivets wscts2018 ljubljana
Kshivets wscts2018 ljubljana
Oleg Kshivets
 
Kshivets Oleg Optimization of Management for Esophageal Cancer Patients (T1-...
Kshivets Oleg  Optimization of Management for Esophageal Cancer Patients (T1-...Kshivets Oleg  Optimization of Management for Esophageal Cancer Patients (T1-...
Kshivets Oleg Optimization of Management for Esophageal Cancer Patients (T1-...
Oleg Kshivets
 
Kshivets barcelona2019
Kshivets barcelona2019Kshivets barcelona2019
Kshivets barcelona2019
Oleg Kshivets
 
Kshivets barcelona2016
Kshivets barcelona2016Kshivets barcelona2016
Kshivets barcelona2016
Oleg Kshivets
 
Kshivets milan2014
Kshivets milan2014Kshivets milan2014
Kshivets milan2014
Oleg Kshivets
 
Kshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer Surgery
Oleg Kshivets
 
Kshivets Hong Kong Sydney2020
Kshivets Hong Kong Sydney2020Kshivets Hong Kong Sydney2020
Kshivets Hong Kong Sydney2020
Oleg Kshivets
 
Kshivets wscts2019 sofia
Kshivets wscts2019 sofiaKshivets wscts2019 sofia
Kshivets wscts2019 sofia
Oleg Kshivets
 
Kshivets_SPB_WSCTS2022Eso.pdf
Kshivets_SPB_WSCTS2022Eso.pdfKshivets_SPB_WSCTS2022Eso.pdf
Kshivets_SPB_WSCTS2022Eso.pdf
Oleg Kshivets
 
Esophageal Cancer: Precise Prediction
Esophageal Cancer: Precise Prediction      Esophageal Cancer: Precise Prediction
Esophageal Cancer: Precise Prediction
Oleg Kshivets
 
• Gastric cancer prognosis and cell ratio factors
•	Gastric cancer prognosis and cell ratio factors           •	Gastric cancer prognosis and cell ratio factors
• Gastric cancer prognosis and cell ratio factors
Oleg Kshivets
 

Similar to Kshivets elcc2022 (20)

Kshivets IASLC_Vienna2016
Kshivets IASLC_Vienna2016Kshivets IASLC_Vienna2016
Kshivets IASLC_Vienna2016
 
Lung Cancer: Precise Prediction
Lung Cancer: Precise PredictionLung Cancer: Precise Prediction
Lung Cancer: Precise Prediction
 
Kshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdfKshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdf
 
Kshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdfKshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdf
 
Kshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer Surgery
 
Kshivets iaslc singapore2020
Kshivets iaslc singapore2020Kshivets iaslc singapore2020
Kshivets iaslc singapore2020
 
Kshivets iaslc denver2015
Kshivets iaslc denver2015Kshivets iaslc denver2015
Kshivets iaslc denver2015
 
Kshivets_SPB_WSCTS2022Lung.pdf
Kshivets_SPB_WSCTS2022Lung.pdfKshivets_SPB_WSCTS2022Lung.pdf
Kshivets_SPB_WSCTS2022Lung.pdf
 
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
 
Kshivets wscts2018 ljubljana
Kshivets wscts2018 ljubljanaKshivets wscts2018 ljubljana
Kshivets wscts2018 ljubljana
 
Kshivets Oleg Optimization of Management for Esophageal Cancer Patients (T1-...
Kshivets Oleg  Optimization of Management for Esophageal Cancer Patients (T1-...Kshivets Oleg  Optimization of Management for Esophageal Cancer Patients (T1-...
Kshivets Oleg Optimization of Management for Esophageal Cancer Patients (T1-...
 
Kshivets barcelona2019
Kshivets barcelona2019Kshivets barcelona2019
Kshivets barcelona2019
 
Kshivets barcelona2016
Kshivets barcelona2016Kshivets barcelona2016
Kshivets barcelona2016
 
Kshivets milan2014
Kshivets milan2014Kshivets milan2014
Kshivets milan2014
 
Kshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer Surgery
 
Kshivets Hong Kong Sydney2020
Kshivets Hong Kong Sydney2020Kshivets Hong Kong Sydney2020
Kshivets Hong Kong Sydney2020
 
Kshivets wscts2019 sofia
Kshivets wscts2019 sofiaKshivets wscts2019 sofia
Kshivets wscts2019 sofia
 
Kshivets_SPB_WSCTS2022Eso.pdf
Kshivets_SPB_WSCTS2022Eso.pdfKshivets_SPB_WSCTS2022Eso.pdf
Kshivets_SPB_WSCTS2022Eso.pdf
 
Esophageal Cancer: Precise Prediction
Esophageal Cancer: Precise Prediction      Esophageal Cancer: Precise Prediction
Esophageal Cancer: Precise Prediction
 
• Gastric cancer prognosis and cell ratio factors
•	Gastric cancer prognosis and cell ratio factors           •	Gastric cancer prognosis and cell ratio factors
• Gastric cancer prognosis and cell ratio factors
 

More from Oleg Kshivets

Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Oleg Kshivets
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Oleg Kshivets
 
Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...
Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...
Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...
Oleg Kshivets
 
Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...
Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...
Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...
Oleg Kshivets
 
Esophageal Cancer: Artificial Intelligence, Synergetics, Complex System Analy...
Esophageal Cancer: Artificial Intelligence, Synergetics, Complex System Analy...Esophageal Cancer: Artificial Intelligence, Synergetics, Complex System Analy...
Esophageal Cancer: Artificial Intelligence, Synergetics, Complex System Analy...
Oleg Kshivets
 
Kshivets_IASLC_Singapore2023.pdf
Kshivets_IASLC_Singapore2023.pdfKshivets_IASLC_Singapore2023.pdf
Kshivets_IASLC_Singapore2023.pdf
Oleg Kshivets
 
KshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfKshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdf
Oleg Kshivets
 
KshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfKshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdf
Oleg Kshivets
 
KshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfKshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdf
Oleg Kshivets
 
Kshivets_WCGIC2023.pdf
Kshivets_WCGIC2023.pdfKshivets_WCGIC2023.pdf
Kshivets_WCGIC2023.pdf
Oleg Kshivets
 
Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...
Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...
Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...
Oleg Kshivets
 
Lung Cancer: 10-Year Survival
Lung Cancer: 10-Year Survival           Lung Cancer: 10-Year Survival
Lung Cancer: 10-Year Survival
Oleg Kshivets
 

More from Oleg Kshivets (12)

Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
 
Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...
Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...
Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...
 
Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...
Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...
Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...
 
Esophageal Cancer: Artificial Intelligence, Synergetics, Complex System Analy...
Esophageal Cancer: Artificial Intelligence, Synergetics, Complex System Analy...Esophageal Cancer: Artificial Intelligence, Synergetics, Complex System Analy...
Esophageal Cancer: Artificial Intelligence, Synergetics, Complex System Analy...
 
Kshivets_IASLC_Singapore2023.pdf
Kshivets_IASLC_Singapore2023.pdfKshivets_IASLC_Singapore2023.pdf
Kshivets_IASLC_Singapore2023.pdf
 
KshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfKshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdf
 
KshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfKshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdf
 
KshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfKshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdf
 
Kshivets_WCGIC2023.pdf
Kshivets_WCGIC2023.pdfKshivets_WCGIC2023.pdf
Kshivets_WCGIC2023.pdf
 
Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...
Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...
Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...
 
Lung Cancer: 10-Year Survival
Lung Cancer: 10-Year Survival           Lung Cancer: 10-Year Survival
Lung Cancer: 10-Year Survival
 

Recently uploaded

Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
taiba qazi
 
Aortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 BernAortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 Bern
suvadeepdas911
 
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.GawadHemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
NephroTube - Dr.Gawad
 
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
bkling
 
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptxPost-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
FFragrant
 
CBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdfCBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdf
suvadeepdas911
 
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
rishi2789
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
rishi2789
 
The Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of RespirationThe Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of Respiration
MedicoseAcademics
 
The Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic PrinciplesThe Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic Principles
MedicoseAcademics
 
Ketone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistryKetone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistry
Dhayanithi C
 
Histopathology of Rheumatoid Arthritis: Visual treat
Histopathology of Rheumatoid Arthritis: Visual treatHistopathology of Rheumatoid Arthritis: Visual treat
Histopathology of Rheumatoid Arthritis: Visual treat
DIVYANSHU740006
 
All info about Diabetes and how to control it.
 All info about Diabetes and how to control it. All info about Diabetes and how to control it.
All info about Diabetes and how to control it.
Gokuldas Hospital
 
LOOPS in orthodontics t loop bull loop vertical loop mushroom loop stop loop
LOOPS in orthodontics t loop bull loop vertical loop mushroom loop stop loopLOOPS in orthodontics t loop bull loop vertical loop mushroom loop stop loop
LOOPS in orthodontics t loop bull loop vertical loop mushroom loop stop loop
debosmitaasanyal1
 
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
rishi2789
 
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachIntegrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Ayurveda ForAll
 
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
Donc Test
 
vonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentationvonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentation
Dr.pavithra Anandan
 
TEST BANK For Community and Public Health Nursing: Evidence for Practice, 3rd...
TEST BANK For Community and Public Health Nursing: Evidence for Practice, 3rd...TEST BANK For Community and Public Health Nursing: Evidence for Practice, 3rd...
TEST BANK For Community and Public Health Nursing: Evidence for Practice, 3rd...
Donc Test
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
Holistified Wellness
 

Recently uploaded (20)

Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
 
Aortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 BernAortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 Bern
 
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.GawadHemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
 
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
 
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptxPost-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
 
CBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdfCBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdf
 
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
 
The Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of RespirationThe Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of Respiration
 
The Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic PrinciplesThe Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic Principles
 
Ketone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistryKetone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistry
 
Histopathology of Rheumatoid Arthritis: Visual treat
Histopathology of Rheumatoid Arthritis: Visual treatHistopathology of Rheumatoid Arthritis: Visual treat
Histopathology of Rheumatoid Arthritis: Visual treat
 
All info about Diabetes and how to control it.
 All info about Diabetes and how to control it. All info about Diabetes and how to control it.
All info about Diabetes and how to control it.
 
LOOPS in orthodontics t loop bull loop vertical loop mushroom loop stop loop
LOOPS in orthodontics t loop bull loop vertical loop mushroom loop stop loopLOOPS in orthodontics t loop bull loop vertical loop mushroom loop stop loop
LOOPS in orthodontics t loop bull loop vertical loop mushroom loop stop loop
 
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
 
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachIntegrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
 
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
 
vonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentationvonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentation
 
TEST BANK For Community and Public Health Nursing: Evidence for Practice, 3rd...
TEST BANK For Community and Public Health Nursing: Evidence for Practice, 3rd...TEST BANK For Community and Public Health Nursing: Evidence for Practice, 3rd...
TEST BANK For Community and Public Health Nursing: Evidence for Practice, 3rd...
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
 

Kshivets elcc2022

  • 1. Phase transition Early-Invasive Lung Cancer and Blood Cell Circuit No disclosures OBJECTIVE: The effect of blood cell circuit on the phase transition (PT) early-invasive lung cancer (LC) was investigated. METHODS: We analyzed data of 770 consecutive non-small cell LC patients (LCP) (age=57.6±8.3 years; tumor size=4.1±2.4 cm) radically operated (R0) and monitored in 1985-2021 (m=661, f=109; upper lobectomies=278, lower lobectomies=177, middle lobectomies=18, bilobectomies=42, pneumonectomies=255, mediastinal lymph node dissection=770; combined procedures with resection of trachea, carina, atrium, aorta, VCS, vena azygos, pericardium, liver, diaphragm, ribs, esophagus=194; T1=321, T2=255, T3=133, T4=61; N0=517, N1=131, N2=122, M0=770; G1=194, G2=243, G3=333; squamous=417, adenocarcinoma=303, large cell=50; early LCP=215; invasive LCP=555; central LC=291; periferical LC=479. Variables selected for study were input levels of blood cell circuit, sex, age, TNMG. Differences between groups were evaluated using discriminant analysis, clustering, nonlinear estimation, structural equation modeling, Monte Carlo, bootstrap simulation and neural networks computing. RESULTS: It was revealed that separation of LCP with early LC (n=215) from invasive LCP (n=555) significantly depended on: Hb, leucocytes (abs, total), thrombocytes (abs, tot), erythrocytes (abs, tot), segmented neutrophils (%, abs, total), stick neutrophils (%, abs, total), lymphocytes (%), monocytes (abs, tot), ESS, coagulation time, fibrinogen, cell ratio factors (CRF) (ratio between cancer cells- CC and blood cells subpopulations), tumor size, age, tumor growth, T1-4, G1-3, PT N0---N12 (P=0.046-0.000). Neural networks computing, genetic algorithm selection and bootstrap simulation revealed relationships of PT early—invasive cancer and CRF: healthy cells/CC (rank=1), erythrocytes/CC (2), stick neutrophils/CC (3), thrombocytes/CC (4), eosinophils/CC (5), segmented neutrophils/CC (6), lymphocytes/CC (7), monocytes/CC (8), leucocytes/CC (9). Correct classification PT early—invasive cancer was 100% by neural networks computing (area under ROC curve=1.0; error=0.0). CONCLUSION: Blood cell circuit significantly influenced the phase transition early—invasive lung cancer. Oleg Kshivets, MD, PhD e-mail: okshivets@yahoo.com Surgery Department, Roshal Hospital, Moscow, Russia a Effect GLZ results Distribution : NORMAL Link function: LOG Degr. of Freedom Wald Stat. p Intercept 1 7.0733 0.007824 Tumor Size 1 17.0855 0.000036 Erythrocytes 1 26.7452 0.000000 Eosinophils 1 10.1318 0.001457 Stick Neutrophils 1 5.3924 0.020225 Segmented Neutrophils 1 7.1446 0.007519 Lymphocytes 1 6.7744 0.009248 Monocytes 1 6.6979 0.009653 Monocytes (abs) 1 6.4758 0.010935 Leucocytes/Cancer Cells 1 12.4650 0.000415 Eosinophils/Cancer Cells 1 5.5420 0.018566 Segmented Neutrophils/Cancer Cells 1 9.1786 0.002449 Lymphocytes/Cancer Cells 1 7.9876 0.004710 Healthy Cells/Cancer Cells 1 54.3179 0.000000 Erythrocytes (tot) 1 25.8367 0.000000 Leucocytes (tot) 1 12.3061 0.000451 Eosinophils (tot) 1 16.5695 0.000047 Stick Neutrophils (tot) 1 9.7226 0.001820 Stick Neutrophils (tot) 1 12.3151 0.000449 Lymphocytes (tot) 1 11.6562 0.000640 Monocytes (tot) 1 5.3094 0.021211 Tumor Growth 1 10.0305 0.001540 G1-3 2 14.4966 0.000711 T1-4 3 145.8011 0.000000 Phase Transition N0----N12 1 61.7560 0.000000 Neural Networks: n=770; Baseline Error=0.000; Area under ROC Curve=1.000; Correct Classification Rate=100% Rank Sensitivity Healthy Cells/Cancer Cells 1 2639 Erythrocytes/Cancer Cells 2 900 Stick Neutrophils/Cancer Cells 3 821 Thrombocytes/Cancer Cells 4 709 Eosinophils/Cancer Cells 5 606 Segmented Neutrophils/Cancer Cells 6 485 Lymphocytes/Cancer Cells 7 372 Monocytes/Cancer Cells 8 342 Leucocytes/Cancer Cells Stick 9 216 Bootstrap Simulation n=770 Significant Factors (Number of Samples=3333) Rank Kendal Tau-A P< Healthy Cells/Cancer Cells 1 0.607 0.000 Erythrocytes/Cancer Cells 2 0.596 0.000 Thrombocytes/Cancer Cells 3 0.561 0.000 Leucocytes/Cancer Cells 4 0.498 0.000 Segmented Neutrophils/Cancer Cells 5 0.472 0.000 Lymphocytes/Cancer Cells 6 0.450 0.000 Tumor Size 7 -0.399 0.000 T1-4 8 -0.317 0.000 Monocytes/Cancer Cells 9 0.263 0.000 Eosinophils/Cancer Cells 10 0.233 0.000 Phase Transition N0---N12 11 -0.183 0.000 Surgery along 12 0.151 0.000 Pneumonectomies/Lobectomies 13 -0.149 0.000 ESS 14 -0.149 0.000 Procedure Type 15 0.148 0.000 Segmented Neutrophils (abs) 16 -0.125 0.000 Coagulation Time 17 -0.109 0.000 G1-3 18 -0.091 0.001 Adjuvant Treatment 19 -0.089 0.001 Tumor Growth 20 0.079 0.05 Stick Neutrophils (abs) 21 -0.076 0.05 Stick Neutrophils (%) 22 -0.074 0.05 Histology 23 0.073 0.05 #358